Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Front Pharmacol ; 8: 641, 2017.
Article in English | MEDLINE | ID: mdl-29033834

ABSTRACT

(E)-5-(Pyrimidin-5-yl)-1,2,3,4,7,8-hexahydroazocine (TC299423) is a novel agonist for nicotinic acetylcholine receptors (nAChRs). We examined its efficacy, affinity, and potency for α6ß2∗ (α6ß2-containing), α4ß2∗, and α3ß4∗ nAChRs, using [125I]-epibatidine binding, whole-cell patch-clamp recordings, synaptosomal 86Rb+ efflux, [3H]-dopamine release, and [3H]-acetylcholine release. TC299423 displayed an EC50 of 30-60 nM for α6ß2∗ nAChRs in patch-clamp recordings and [3H]-dopamine release assays. Its potency for α6ß2∗ in these assays was 2.5-fold greater than that for α4ß2∗, and much greater than that for α3ß4∗-mediated [3H]-acetylcholine release. We observed no major off-target binding on 70 diverse molecular targets. TC299423 was bioavailable after intraperitoneal or oral administration. Locomotor assays, measured with gain-of-function, mutant α6 (α6L9'S) nAChR mice, show that TC299423 elicits α6ß2∗ nAChR-mediated responses at low doses. Conditioned place preference assays show that low-dose TC299423 also produces significant reward in α6L9'S mice, and modest reward in WT mice, through a mechanism that probably involves α6(non-α4)ß2∗ nAChRs. However, TC299423 did not suppress nicotine self-administration in rats, indicating that it did not block nicotine reinforcement in the dosage range that was tested. In a hot-plate test, TC299423 evoked antinociceptive responses in mice similar to those of nicotine. TC299423 and nicotine similarly inhibited mouse marble burying as a measure of anxiolytic effects. Taken together, our data suggest that TC299423 will be a useful small-molecule agonist for future in vitro and in vivo studies of nAChR function and physiology.

2.
Neuropsychopharmacology ; 42(12): 2285-2291, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28401925

ABSTRACT

Understanding why the quit rate among smokers of menthol cigarettes is lower than non-menthol smokers requires identifying the neurons that are altered by nicotine, menthol, and acetylcholine. Dopaminergic (DA) neurons in the ventral tegmental area (VTA) mediate the positive reinforcing effects of nicotine. Using mouse models, we show that menthol enhances nicotine-induced changes in nicotinic acetylcholine receptors (nAChRs) expressed on midbrain DA neurons. Menthol plus nicotine upregulates nAChR number and function on midbrain DA neurons more than nicotine alone. Menthol also enhances nicotine-induced changes in DA neuron excitability. In a conditioned place preference (CPP) assay, we observed that menthol plus nicotine produces greater reward-related behavior than nicotine alone. Our results connect changes in midbrain DA neurons to menthol-induced enhancements of nicotine reward-related behavior and may help explain how smokers of menthol cigarettes exhibit reduced cessation rates.


Subject(s)
Dopaminergic Neurons/physiology , Menthol/administration & dosage , Nicotine/administration & dosage , Receptors, Nicotinic/physiology , Reward , Up-Regulation/physiology , Action Potentials/drug effects , Action Potentials/physiology , Animals , Cell Line , Dopaminergic Neurons/drug effects , Dose-Response Relationship, Drug , Drug Synergism , Mesencephalon/cytology , Mesencephalon/drug effects , Mesencephalon/physiology , Mice , Mice, Inbred C57BL , Mice, Transgenic , Organ Culture Techniques , Up-Regulation/drug effects
3.
J Neurosci ; 36(10): 2957-74, 2016 Mar 09.
Article in English | MEDLINE | ID: mdl-26961950

ABSTRACT

Upregulation of ß2 subunit-containing (ß2*) nicotinic acetylcholine receptors (nAChRs) is implicated in several aspects of nicotine addiction, and menthol cigarette smokers tend to upregulate ß2* nAChRs more than nonmenthol cigarette smokers. We investigated the effect of long-term menthol alone on midbrain neurons containing nAChRs. In midbrain dopaminergic (DA) neurons from mice containing fluorescent nAChR subunits, menthol alone increased the number of α4 and α6 nAChR subunits, but this upregulation did not occur in midbrain GABAergic neurons. Thus, chronic menthol produces a cell-type-selective upregulation of α4* nAChRs, complementing that of chronic nicotine alone, which upregulates α4 subunit-containing (α4*) nAChRs in GABAergic but not DA neurons. In mouse brain slices and cultured midbrain neurons, menthol reduced DA neuron firing frequency and altered DA neuron excitability following nAChR activation. Furthermore, menthol exposure before nicotine abolished nicotine reward-related behavior in mice. In neuroblastoma cells transfected with fluorescent nAChR subunits, exposure to 500 nm menthol alone also increased nAChR number and favored the formation of (α4)3(ß2)2 nAChRs; this contrasts with the action of nicotine itself, which favors (α4)2(ß2)3 nAChRs. Menthol alone also increases the number of α6ß2 receptors that exclude the ß3 subunit. Thus, menthol stabilizes lower-sensitivity α4* and α6 subunit-containing nAChRs, possibly by acting as a chemical chaperone. The abolition of nicotine reward-related behavior may be mediated through menthol's ability to stabilize lower-sensitivity nAChRs and alter DA neuron excitability. We conclude that menthol is more than a tobacco flavorant: administered alone chronically, it alters midbrain DA neurons of the nicotine reward-related pathway.


Subject(s)
Action Potentials/drug effects , Dopaminergic Neurons/drug effects , Dopaminergic Neurons/metabolism , Menthol/pharmacology , Mesencephalon/cytology , Nicotine/administration & dosage , Receptors, Nicotinic/metabolism , Reward , Up-Regulation/drug effects , Acetylcholine/pharmacology , Animals , Cell Line, Tumor , Cells, Cultured , Conditioning, Operant/drug effects , Conditioning, Operant/physiology , Exocytosis/drug effects , Exocytosis/genetics , Luminescent Proteins/genetics , Luminescent Proteins/metabolism , Mesencephalon/metabolism , Mice , Mice, Inbred C57BL , Mice, Transgenic , Neuroblastoma/pathology , Nicotinic Agonists/administration & dosage , Protein Subunits/genetics , Protein Subunits/metabolism , Receptors, Nicotinic/genetics , Time Factors , Up-Regulation/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...